ArticleObesity pillars2026

Orforglipron for obesity treatment in older patients ≥65 years with or without type 2 diabetes: A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials.

Deborah B Horn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.